Novartis AG (NVS): Price and Financial Metrics

NVS POWR Grades

• NVS scores best on the Stability dimension, with a Stability rank ahead of 98.26% of US stocks.
• The strongest trend for NVS is in Growth, which has been heading down over the past 179 days.
• NVS ranks lowest in Momentum; there it ranks in the 17th percentile.

NVS Stock Summary

• With a market capitalization of $175,334,460,000, NOVARTIS AG has a greater market value than 99.09% of US stocks.
• Over the past twelve months, NVS has reported earnings growth of 119.03%, putting it ahead of 87.06% of US stocks in our set.
• In terms of volatility of its share price, NVS is more volatile than just 1.09% of stocks we're observing.
• Stocks that are quantitatively similar to NVS, based on their financial statements, market capitalization, and price volatility, are AZN, CSCO, TXN, RTX, and BMY.
• NVS's SEC filings can be seen here. And to visit NOVARTIS AG's official web site, go to www.novartis.com.

NVS Valuation Summary

• In comparison to the median Healthcare stock, NVS's price/sales ratio is 50% higher, now standing at 3.3.
• Over the past 243 months, NVS's price/sales ratio has gone down 2.7.

Below are key valuation metrics over time for NVS.

NVS Growth Metrics

The 3 year cash and equivalents growth rate now stands at 103.5%.
• Its year over year price growth rate is now at 2.68%.
• Its 3 year price growth rate is now at 14.32%.

Over the past 15 months, NVS's revenue has gone up $2,904,000,000.

The table below shows NVS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	52,788	14,213	22,982
2022-03-31	52,997	14,590	24,184
2021-12-31	52,877	15,071	24,021
2021-09-30	52,385	15,192	9,807
2021-06-30	51,556	13,423	8,984
2021-03-31	49,884	13,252	7,955

NVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NVS has a Quality Grade of B, ranking ahead of 86.01% of graded US stocks.
• NVS's asset turnover comes in at 0.42 -- ranking 108th of 682 Pharmaceutical Products stocks.
• GHSI, KALA, and ADAP are the stocks whose asset turnover ratios are most correlated with NVS.

The table below shows NVS's key quality metrics over time.